MM&M's Hall of Femme: 16 women leaders who changed the industry

The 16 women profiled here number among those who have bridged the gender gap in agencies, biopharma, and medtech.

MM&M's Hall of Femme: 20 women to watch

The MM&M Women to Watch, part of our inaugural Hall of Femme, salutes 20 aspiring healthcare commercial and marketing execs distinguishing themselves.

Five things for pharma marketers to know: Friday, April 29, 2016

Five things for pharma marketers to know: Friday, April 29, 2016

Harvoni and Sovaldi growth begins to slow; drugmakers spend billions to buy developers of cancer therapies; Valeant discloses new investigations

Bristol-Myers Squibb plans to spend more on DTC for Opdivo

Bristol-Myers Squibb plans to spend more on DTC for Opdivo

The drugmaker said it plans to increase its investment in DTC for the immuno-oncology drug.

Five things for pharma marketers to know: Thursday, April 28, 2016

Five things for pharma marketers to know: Thursday, April 28, 2016

Pfizer settles rebate suit; Sanofi moves to acquire Medivation; AstraZeneca sells US rights to gout drug

Senate committee condemns Valeant's business model

Senate committee condemns Valeant's business model

The Senate committee on Aging said Valeant's missteps go beyond price hikes and that its business model is fundamentally to blame.

Publicis Healthcare names Jarecke-Cheng global comms chief

Publicis Healthcare names Jarecke-Cheng global comms chief

Publicis Healthcare Communications Group has hired Kipp Jarecke-Cheng as global chief communications officer.

Five things for pharma marketers to know: Wednesday, April 27, 2016

Five things for pharma marketers to know: Wednesday, April 27, 2016

Pearson expected to say price hikes were too aggressive; Collegium's painkiller receives full FDA approval; most hospitals stop advertising infant formula

Infographic: the growing biosimilar market in the U.S.

Infographic: the growing biosimilar market in the U.S.

The FDA has approved two biosimilars, but questions remain about how quickly providers and patients in the U.S. will adopt them.

Following positive outcomes data, a new diabetes class is on the rise

Following positive outcomes data, a new diabetes class is on the rise

Eli Lilly noted in its first-quarter earnings report that SGLT2 inhibitors, a treatment for type 2 diabetes patients, are surging.

Five things for pharma marketers to know: Tuesday, April 26, 2016

Five things for pharma marketers to know: Tuesday, April 26, 2016

FDA panel says Duchenne drug is not effective; Bill Ackman to appear before Senate committee investigating pricing issues; Daiichi Sankyo to open new headquarters

About.com launches first standalone health site Verywell

About.com launches first standalone health site Verywell

Verywell.com presents physician-reviewed health and wellness content that aims to be "gentler" than other health websites.

Agency Spotlight


OPINION


Click here to learn about the Agency Issue. 

Email Newsletters